Sign In
Buy JAZZ
$252.86
-5.52 (-2.14%)
At Close: Jul 31, 2026
Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
10:51am, Tuesday, 19'th May 2026
Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the D
Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?
09:00am, Wednesday, 13'th May 2026
JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
04:15pm, Tuesday, 12'th May 2026
DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock
10:51am, Tuesday, 12'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
International Markets and Jazz (JAZZ): A Deep Dive for Investors
10:16am, Monday, 11'th May 2026
Examine the evolution of Jazz's (JAZZ) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
10:40am, Friday, 08'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It
04:21pm, Wednesday, 06'th May 2026
Jazz Pharmaceuticals remains a Strong Buy, with Q1 2026 results affirming robust growth and a successful pivot into oncology. JAZZ's oncology segment, led by Ziihera, Modeyso, and Zepzelca, is driving
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
11:32am, Wednesday, 06'th May 2026
Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
02:51am, Wednesday, 06'th May 2026
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
09:31pm, Tuesday, 05'th May 2026
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street est
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
07:05pm, Tuesday, 05'th May 2026
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.34 per share, beating the Zacks Consensus Estimate of $4.67 per share. This compares to earnings of $1.68 per share a year ago.
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
04:05pm, Tuesday, 05'th May 2026
– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xy
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
11:07am, Tuesday, 28'th Apr 2026
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced th
